Georgina V Long, Andrew Spillane, Thomas Pennington, Kerwin F Shannon, Jonathon R Stretch, Maria Gonzalez, Robyn PM Saw, Serigne Lo, Richard A Scolyer, Alexander M Menzies
To determine the the pathological response rate to 6 weeks of neoadjuvant pembrolizumab plus lenvatinib, and to determine the RECIST and metabolic response at week 6, the relapse free survival and to evaluate the effects on tumour tissue and peripheral blood.
J. Braden, A.J. Potter, E. Paver, R Rawson, A M. Menzies, M.S. Carlino, G. Au-Yeung, R.P.M. Saw, A.J. Spillane, K.F. Shannon, T. E. Pennington, S. Ch’ng, D. E. Gyorki, J. Howle, D. Daneshvar, J.S. Wilmott, S. E. Lo, I.P. Silva, R.A. Scolyer, G.V. Long
To characterise key histopathological changes with neoadjuvant targeted therapy (TT), anti-PD-1 or combination and their association with pathological response.
Alexander HR Varey, Mary-Ann El Sharouni, Julie Simon, Jeffrey E. Gershenwald, Georgina V. Long, Richard A. Scolyer, John F. Thompson, Serigne N. Lo
To develop a user-friendly externally validated tool for predicting relapse free survival (RFS) and overall survival (OS) in stage II melanoma patients (with or without sentinel node biopsy).
Amelia M Taylor, Claire Galea, Isabel Li, Alexander HR Varey, Kerwin Shannon, Sydney Ch’ng, Robyn PM Saw, Thomas Pennington, Jonathan Stretch, Andrew Spillane, Alexander C J van Akkooi, Ines P da Silva, Matteo S Carlino, Richard A Scolyer, Georgina V Long, Serigne Lo, Alexander M Menzies
To develop a web app to guide discussions about risk of recurrence with or without therapy at baseline and during a patient’s treatment journey.
Sarah Jacques, Janet McKeown, Piyush Grover, Benjamin Park, Anne Zaremba, FlorentinaDimitriou, Mohamad Farid, Kenjiro Namikawa, Megan Mooradian, Joanna Placzke, Clare Allayous, InderjitMehmi, Danielle Depalo, Alexandre Wicky, Julia Schwarze, Yasuhiro Nakamura, SeverineRoy, Alex Menzies, SerigneLo, Matteo Carlino
Determine risk of recurrence of resected acral melanomas (AM) and mucosal melanomas (MM) following adjuvant anti-PD-1, and quantify the effect of adjuvant anti-PD-1 in AM and MM compared to a historical matched cohort.
J. Mo, S. Bohne, C. Gaudy Marqueste, N. Della Marta , L. Festino, C. Chen, S. Lo, J. Park, P. Ascierto, R. Ladwa, W. Xu, J J. Grob, A. Hauschild. A. Menzies, GV. Long, M. Carlino, I. Pires da Silva
For advanced cutaneous Squamous Cell Carcinoma evaluate site specific patterns of response to anti PD-(L)1 and study the management following progression to anti PD-(L)1.
J. Mo, A. Zaremba, J. Inderjeeth , P. El Zenaity, A. Li, A. Wicky, N. Della Marta, C. Gaudy Marqueste, S. Bohne, L. Festino, C. Chen, S. Lo, A. Guminski, O. Michielin, W. Xu, C. Lebbe, S. Sandhu, L. Zimmer, M. Carlino, I. Pires da Silva
For Merkel Cell Carcinoma evaluate site specific patterns of response of to anti PD-(L)1 and study the management following progression to anti PD-(L)1.